サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1696283

止血マトリックスの世界市場（2025年～2033年）

Global Hemostatic Matrix Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
止血マトリックスの世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の止血マトリックスの市場規模は、2024年に27億4,000万米ドルに達し、2033年までに39億1,000万米ドルに達すると予測され、2025年～2033年の予測期間にCAGRで4.8%の成長が見込まれます。

止血マトリックスは、外科手術中の出血をコントロールする特殊な医療製品です。多くの場合、流動性のゼラチンマトリックスとトロンビン成分が組み合わされており、血液凝固を速やかに促進します。この組み合わせは、焼灼、結紮、縫合といった従来の方法が有効でない場合に特に有用であり、例えば表面積が広い場合や出血部位へのアクセスが困難な場合などです。

外科手術、特に外傷治療の件数の増加は、止血マトリックス市場の主な促進要因です。例えば、世界保健機関（WHO）のデータによると、交通事故によって年間119万人を超える人々の命が奪われており、これらの犠牲者の多くが、迅速な外科的介入を必要とする重度の出血を経験しています。

このことは、患者の予後を向上させる出血のコントロールが重要な外傷手術において、効果的な止血剤の必要性が高まっていることを明示しています。このような製品の需要は、特に事故率が高い地域や救急医療インフラが発達している地域において、外傷関連の手術件数が増加するにつれて拡大すると予測されます。止血技術の進歩により、より効果的で汎用性の高い製品が開発され、手術の効率と患者の安全性の両方が向上していることも、この需要に拍車をかけています。

市場力学

促進要因と抑制要因

手術件数の増加

世界の止血マトリックス市場は複数の重要な促進要因によって拡大しており、その主因は外科手術の増加です。世界的な高齢化に伴い、関節置換術や心血管手術などの手術を必要とする、加齢に関連した健康問題の有病率が増加しています。バージニア大学のニュースによると、2030年までに米国人口の20%が65歳を超えると予測されており、このような種類の手術に対する需要が大幅に増加します。この動向は、複雑な外科手術中の出血をコントロールすることにとって重要な、止血マトリックス製品に対するニーズを促進すると予測されます。

人口統計学的要因に加えて、業界の主要企業による革新的な製品の上市が市場成長をさらに後押ししています。例えば、Olympusは2023年4月、消化管手術向けに設計された止血剤製品群であるEndoClotのポートフォリオを発表しました。これには、止血を助け、内視鏡的粘膜下層剥離術（ESD）や内視鏡的粘膜切除術（EMR）などの手術に特に有益な粘膜下注入液を提供する製品が含まれます。これらの製品は、内視鏡的手術の際、粘膜の浮き上がりを長時間維持し、手術の有効性と安全性を高めるのに役立ちます。

より多くの外科手術が実施され、先進の効果的な出血コントロールソリューションに対する需要が高まる中、こうした人口統計学的動向と技術革新が世界の止血マトリックス市場の主な成長促進要因となっています。これらすべての要因が、世界の止血マトリックス市場を要求します。

製品リコール

製品リコールは、多額の金銭的損失やブランドの評判へのダメージにつながる可能性があり、もっとも重要なこととして患者の安全性にリスクをもたらすため、世界の止血マトリックス市場にとっての大きな抑制要因となっています。こうしたリコールは、製品の使用中や品質管理プロセスを通じて安全性や有効性の問題が確認された場合に発生することが多いです。止血剤に効果がない、汚染されている、またはその他の点で問題があることが判明した場合、出血の制御不能や感染症などの有害な手術結果につながる可能性があり、患者の健康が脅かされます。

例えば2024年9月、Baxter Healthcareは、安定性試験中に検出された問題により、Tisseel Lyo Fibrin Sealant Kitsの特定のバッチについて自主回収を発表しました。これらのキットはさまざまな外科手術で使用されており、このリコールは、特に患者の転帰に直接影響する医療機器について、製品の品質と安全性を確保することの重要性を強く示しています。このようなリコールは、何らかの欠陥があれば手術中に重篤な合併症を引き起こす可能性があることから、止血製品に関連する潜在的なリスクを浮き彫りにしています。そのため、上記のような要因が世界の止血材市場の潜在的な成長を制限している可能性があります。

当レポートでは、世界の止血マトリックス市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：製品タイプ別
  • 抜粋：形状別
  • 抜粋：用途別
  • 抜粋：エンドユーザー別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 外科手術の増加
      • 止血製品の革新
    • 抑制要因
      • 製品リコール
      • 副作用のリスク
    • 機会
      • 低侵襲手術の成長
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 止血マトリックス市場：製品タイプ別

  • ゼラチンベース止血マトリックス
  • コラーゲンベース止血マトリックス
  • トロンビンベース止血マトリックス
  • 複合止血マトリックス
  • その他

第6章 止血マトリックス市場：形状別

  • ゲル
  • フォーム
  • 粉末
  • ペースト

第7章 止血マトリックス市場：用途別

  • 外科手術
    • 心血管手術
    • 整形外科手術
    • 脳神経手術
    • 一般外科手術
    • 婦人科手術
    • 泌尿器科手術
    • その他
  • 外傷ケア
  • 創傷ケア
  • その他

第8章 止血マトリックス市場：エンドユーザー別

  • 病院
  • 外来手術センター
  • 外傷センター
  • その他

第9章 止血マトリックス市場：地域別、市場の分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Pfizer Inc.
  • Ethicon (Johnson & Johnson)
  • Baxter International Inc.
  • Becton, Dickinson and Company (BD)
  • B. Braun SE
  • Integra LifeSciences Corporation.
  • CryoLife, Inc. (Artivion, Inc)
  • Advanced Medical Solutions Group plc
  • Aegis Lifesciences
  • Teleflex Incorporated.
  • HLB Cell

第12章 前提条件と調査手法

第13章 付録

目次
Product Code: MD8719

The global hemostatic matrix market reached US$ 2.74 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 4.8% during the forecast period of 2025-2033.

A hemostatic matrix is a specialized medical product that controls bleeding during surgical procedures. It often combines a flowable gelatin matrix with a thrombin component, working together to facilitate rapid blood clotting. This combination is particularly valuable when traditional methods like cautery, ligatures, or sutures might not be effective, such as in cases involving large surface areas or difficult-to-access bleeding sites.

The growing number of surgical procedures, especially in trauma care, is a key driver for the hemostatic matrix market. For example, according to World Health Organization (WHO) data, road traffic accidents claim the lives of over 1.19 million people annually, with many of these victims experiencing severe bleeding that requires prompt surgical intervention.

This highlights the increasing need for effective hemostatic agents in trauma surgeries, where bleeding control is crucial for improving patient outcomes. The demand for such products is expected to grow as the number of trauma-related surgeries rises, particularly in regions with high rates of accidents or where emergency medical infrastructure is developing. This demand is further fueled by advancements in hemostatic technology, which has led to the development of more effective and versatile products, enhancing both surgical efficiency and patient safety.

Market Dynamics: Drivers & Restraints

Increasing Number of Surgical Procedures

The global hemostatic matrix market is expanding due to several key drivers, with the rise in surgical procedures being a primary factor. As the global population ages, there is an increasing prevalence of age-related health issues that necessitate surgeries, such as joint replacements and cardiovascular procedures. According to University of Virginia news, it is projected that by 2030, 20% of the U.S. population will be over the age of 65, which will significantly increase the demand for these types of surgeries This trend is expected to drive the need for hemostatic matrix products, which are crucial for controlling bleeding during complex surgical procedures.

In addition to demographic factors, innovative product launches by key players in the industry are further fueling market growth. For example, in April 2023, Olympus introduced its EndoClot portfolio, a line of hemostatic agents designed for gastrointestinal procedures. This includes products that aid in hemostasis and provide a submucosal injection solution, which is particularly beneficial for procedures such as endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). These products help maintain a long-lasting mucosal lift during endoscopic procedures, enhancing both surgical effectiveness and safety.

Together, these demographic trends and technological innovations are key factors driving the growth of the global hemostatic matrix market, as more surgical procedures are performed and demand for advanced, effective bleeding control solutions increases. All these factors demand the global hemostatic matrix market.

Product Recalls

Product recalls represent a significant restraint in the global hemostatic matrix market, as they can lead to substantial financial losses, damage to brand reputation, and, most importantly, pose risks to patient safety. These recalls often occur when safety or efficacy issues are identified during product usage or through quality control processes. If a hemostatic agent is found to be ineffective, contaminated, or otherwise compromised, it can lead to adverse surgical outcomes such as uncontrolled bleeding or infections, which jeopardize patient health.

For example, in September 2024, Baxter Healthcare issued a voluntary recall for certain batches of its Tisseel Lyo Fibrin Sealant Kits due to issues detected during stability studies. These kits are used in various surgical procedures, and the recall underscores the importance of ensuring product quality and safety, especially for medical devices that directly affect patient outcomes. Such recalls highlight the potential risks associated with hemostatic products, as any defect can result in severe complications during surgeries. Thus, the above factors could be limiting the global hemostatic matrix market's potential growth.

Segment Analysis

The global hemostatic matrix market is segmented based on product type, form, application, end-user, and region.

Product Type:

The thrombin-based hemostatic matrix segment in product type is expected to dominate the global hemostatic matrix market with the highest market share

The thrombin-based hemostatic matrix products are designed to control bleeding during surgical procedures, particularly in situations where traditional methods, such as ligatures or cautery, are either impractical or ineffective. The matrix combines a gelatin-based substance with thrombin, an enzyme that promotes clot formation.

This combination enhances hemostasis through two primary mechanisms: mechanical action, where the matrix physically compresses the bleeding area, and biochemical action, where thrombin catalyzes the formation of a clot. The effectiveness of thrombin-based hemostatic matrices in controlling bleeding makes them invaluable across various clinical settings, particularly in cardiovascular, orthopedic, and trauma surgeries. These matrices are especially crucial in situations where surgeons need immediate bleeding control and other methods cannot achieve the desired results.

Research and development in the segment have further solidified its market position. For instance, a meta-analysis from an NCBI study in October 2023 focused on the effectiveness of Floseal, a thrombin-based hemostatic matrix, in minimizing blood loss during total knee arthroplasty (TKA). The study highlighted ongoing debates in the medical community about the matrix's ability to reduce transfusion requirements during TKA surgeries.

While some randomized controlled trials (RCTs) have demonstrated their benefits, other studies have questioned their overall effectiveness. Nevertheless, the growing body of research in this area continues to reinforce the relevance of thrombin-based matrices in surgery, especially for high-risk or complex procedures. This focus on clinical efficacy and product development by key industry players is expected to drive continued growth in the thrombin-based hemostatic matrix segment, ensuring its dominance within the broader hemostatic matrix market.

Geographical Analysis

North America is expected to hold a significant position in the global hemostatic matrix market with the highest market share

In the North America region hemostatic matrix market is due to several critical factors. A major driver is the rising prevalence of chronic diseases, particularly cardiovascular diseases (CVD), diabetes, and obesity, all of which often require surgical intervention.

As CVD rates continue to increase, the demand for cardiovascular surgeries such as coronary artery bypass grafting (CABG), valve replacements, and other cardiac procedures also rises. According to the American Heart Association, in July 2024, more than 184 million people are expected to be affected by some form of CVD by 2050, and the total costs related to CVD are projected to triple to approximately $1.8 trillion. This trend underscores the growing need for effective hemostatic solutions to control bleeding during these complex procedures, further driving demand for hemostatic matrix products.

Additionally, North America benefits from a robust healthcare infrastructure, the presence of numerous key industry players, and strong government initiatives and regulatory support. This combination facilitates the rapid adoption of innovative medical technologies.

A notable example of innovation in the region is the approval of ETHIZIA, a hemostatic sealing patch by Ethicon, a Johnson & Johnson MedTech company. In November 2023, Ethicon received approval for ETHIZIA, a product designed to address challenging bleeding situations during surgeries. The patch is unique for its synthetic polymer technology, which makes it effective on both sides, allowing it to be used in both open and minimally invasive surgeries. ETHIZIA demonstrated the ability to stop bleeding in 80% of patients within 30 seconds, which is significantly faster than traditional fibrin sealant patches

These factors, along with continued investment in product development, clinical trials, and regulatory approvals, are solidifying North America's position as a dominant force in the hemostatic matrix market. The region's well-established healthcare system and commitment to medical innovation make it a primary hub for the adoption of advanced hemostatic solutions.

Competitive Landscape

The major global players in the hemostatic matrix market include Pfizer Inc., Ethicon (Johnson & Johnson), Baxter International Inc., Becton, Dickinson and Company (BD), B. Braun SE, Integra LifeSciences Corporation., CryoLife, Inc. (Artivion, Inc), Advanced Medical Solutions Group plc, Aegis Lifesciences, Teleflex Incorporated., and HLB Cell among others.

Key Developments

  • In July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the United States, enhancing its portfolio of surgical innovations. PERCLOT is a passive, absorbable hemostatic agent designed for patients with intact coagulation systems. It is primarily used to manage mild bleeding during various surgical procedures, offering a non-invasive solution to control bleeding without requiring additional interventions.
  • In March 2023, Axio Biosolutions, a med-tech company based in Bengaluru, achieved a significant milestone by receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ax-Surgi Surgical Hemostat. This approval marks Ax-Surgi as the first chitosan-based hemostatic agent cleared for use in controlling severe surgical bleeding, positioning it as a breakthrough product in managing high-risk bleeding situations during surgeries.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global hemostatic matrix market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Form
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Number of Surgical Procedures
      • 3.1.1.2. Innovations in Hemostatic Products
    • 3.1.2. Restraints
      • 3.1.2.1. Product Recalls
      • 3.1.2.2. Risk of Adverse Reactions
    • 3.1.3. Opportunity
      • 3.1.3.1. Growth in Minimally Invasive Surgeries
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Hemostatic Matrix Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index By Product Type
  • 5.2. Gelatin-based Hemostatic Matrix*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Collagen-based Hemostatic Matrix
  • 5.4. Thrombin-based Hemostatic Matrix
  • 5.5. Combination Hemostatic Matrix
  • 5.6. Others

6. Hemostatic Matrix Market, By Form

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 6.1.2. Market Attractiveness Index By Form
  • 6.2. Gel*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Foam
  • 6.4. Powder
  • 6.5. Paste

7. Hemostatic Matrix Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index By Application
  • 7.2. Surgical Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Cardiovascular Surgery
    • 7.2.4. Orthopedic Surgery
    • 7.2.5. Neurosurgery
    • 7.2.6. General Surgery
    • 7.2.7. Gynecological Surgery
    • 7.2.8. Urology Surgery
    • 7.2.9. Others
  • 7.3. Trauma Care
  • 7.4. Wound Care
  • 7.5. Others

8. Hemostatic Matrix Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Trauma Centers
  • 8.5. Others

9. Hemostatic Matrix Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Pfizer Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Ethicon (Johnson & Johnson),
  • 11.3. Baxter International Inc.
  • 11.4. Becton, Dickinson and Company (BD)
  • 11.5. B. Braun SE
  • 11.6. Integra LifeSciences Corporation.
  • 11.7. CryoLife, Inc. (Artivion, Inc)
  • 11.8. Advanced Medical Solutions Group plc
  • 11.9. Aegis Lifesciences
  • 11.10. Teleflex Incorporated.
  • 11.11. HLB Cell

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us